Research

Hormonal

GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual GIP/GLP-1 agonists (Tirzepatide) offer superior weight loss compared to older anti-obesity medications.

Newer injectable medications like Semaglutide and Tirzepatide provide significantly greater weight loss than older drugs. They are taken weekly and are highly effective, but access and cost can be barriers.

GoodSupportsHIGH confidence
Recently, semaglutide and tirzepatide have been attracting attention because of their effectiveness and convenience...
Won Jun Kim · Korean Journal of Gastroenterology · 2024

Why this rating

Based on clinical trials cited in the review.

Source

Current State of Pharmacotherapy in Obesity

Won Jun Kim · Korean Journal of Gastroenterology · 2024

DOI 10.4166/kjg.2024.016

narrative_reviewCited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →